LONG MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 04:34:37 2024-07-03 am EDT | ||
| 6.82 EUR | +3.81% |
|
| Current month | -4.92% | ||
| 1 month | -30.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 6.82 | +3.81% |
| 24-07-02 | 6.57 | -3.24% |
| 24-07-01 | 6.79 | -1.74% |
| 24-06-28 | 6.91 | -7.87% |
| 24-06-27 | 7.5 | -0.66% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 04:34 am EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VF3BZ3 |
| ISIN | DE000VF3BZ39 |
| Date issued | 2019-02-25 |
| Strike | 1,224 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.44 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.92 € |
|---|---|
| Lowest since issue | 1.07 € |
| Spread | 0.02 € |
| Spread % | 0.29% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,720
DKK
Average target price
2,464
DKK
Spread / Average Target
+43.30%
- Stock Market
- Certificates
- Certificat
